share_log

424B2: Prospectus

424B2: Prospectus

424B2:募资说明书
美股SEC公告 ·  08/02 17:31
Moomoo AI 已提取核心信息
JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the pricing of $4,773,000 in Auto Callable Contingent Interest Notes linked to the common stock of DexCom, Inc., with a due date of August 5, 2026. The notes, which are designed for investors seeking a Contingent Interest Payment on each Review Date where DexCom's stock closes above 50% of its initial value, will be automatically called if DexCom's stock price meets or exceeds the initial value on any Review Date, excluding the first and final dates. The first possible automatic call date is January 31, 2025. The notes are unsecured and unsubordinated, with JPMorgan Chase & Co. providing a full and unconditional guarantee. The notes were priced on July 31, 2024, with...Show More
JPMorgan Chase Financial Company LLC, a wholly owned subsidiary of JPMorgan Chase & Co., has announced the pricing of $4,773,000 in Auto Callable Contingent Interest Notes linked to the common stock of DexCom, Inc., with a due date of August 5, 2026. The notes, which are designed for investors seeking a Contingent Interest Payment on each Review Date where DexCom's stock closes above 50% of its initial value, will be automatically called if DexCom's stock price meets or exceeds the initial value on any Review Date, excluding the first and final dates. The first possible automatic call date is January 31, 2025. The notes are unsecured and unsubordinated, with JPMorgan Chase & Co. providing a full and unconditional guarantee. The notes were priced on July 31, 2024, with an expected settlement date around August 5, 2024. The notes are not bank deposits, are not FDIC insured, and involve a number of risks, including the potential loss of principal and the possibility of receiving no Contingent Interest Payments. The offering includes minimum denominations of $1,000 and integral multiples thereof. The notes are subject to the credit risk of both the issuer and guarantor, and their value may be affected by the creditworthiness of JPMorgan Financial and JPMorgan Chase & Co.
摩根大通金融公司的全资子公司JPMorgan Chase公司宣布定价为477.3万美元的自动购回权环形利息票据,该票据与德康医疗公司的普通股相关联,截止日期为2026年8月5日。该票据旨在满足寻求在每个复审日期上获得有条件利息支付的投资者,在此日期中,德康医疗公司的股票收盘价高过其初始价值的50%。如果在任何复审日期中,德康医疗公司的股票价格达到或超过初始价值,但第一和最后日期除外,那么将自动调用票据。第一个可能的自动调用日期是2025年1月31日。该票据未得到担保,摩根大通公司提供完全无条件担保。该票据的定价日期为2024年7月31日,预计结算日期为2024年8月5日。该票据不是银行存款,也不受FDIC保险保护,包括可能遭受损失和可能未收到有条件利息支付等多种风险。发行包括1000美元的最小面值和其整数倍。该票据受发行人和保证人的信用风险所影响,其价值可能会受到JPMorgan金融和JPMorgan Chase公司的信用评级的影响。
摩根大通金融公司的全资子公司JPMorgan Chase公司宣布定价为477.3万美元的自动购回权环形利息票据,该票据与德康医疗公司的普通股相关联,截止日期为2026年8月5日。该票据旨在满足寻求在每个复审日期上获得有条件利息支付的投资者,在此日期中,德康医疗公司的股票收盘价高过其初始价值的50%。如果在任何复审日期中,德康医疗公司的股票价格达到或超过初始价值,但第一和最后日期除外,那么将自动调用票据。第一个可能的自动调用日期是2025年1月31日。该票据未得到担保,摩根大通公司提供完全无条件担保。该票据的定价日期为2024年7月31日,预计结算日期为2024年8月5日。该票据不是银行存款,也不受FDIC保险保护,包括可能遭受损失和可能未收到有条件利息支付等多种风险。发行包括1000美元的最小面值和其整数倍。该票据受发行人和保证人的信用风险所影响,其价值可能会受到JPMorgan金融和JPMorgan Chase公司的信用评级的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息